By CapitalSnitch Research Desk · updated Oct 23, 2026 · data from SEC filings and official Congress disclosures
Over the past year there were no insider purchases at ArriVent BioPharma, Inc.. One insider sold roughly $13 million instead.
That's worth context: executives sell for plenty of routine reasons, from scheduled trading plans to tax bills. Buying is the rarer, more telling signal.
On the institutional side, 158 funds reported holding AVBP at the end of Q2 2026, and more funds bought than sold. No open-market insider buying or selling in the last full quarter. Insiders bought in 0 of the last 7 full quarters.
The full AVBP report
This page shows the insider trades. The full AVBP report shows everything around them.
Price and valuation, revenue and profit by quarter, who owns it, dilution, earnings timing and a written bull
& bear case, in one report you can also print or save as a PDF. Here is what each section looks like
(screenshots from a real report):
Live price & key numbersScoutPrice, market cap, P/E, revenue and profit growth at a glance.
Bull case vs bear caseAnalystA written read of everything below: what supports the stock, what worries.
Insider signal scoreFreeA 0-100 score with the reasons, plus earnings date, volatility and analyst ratings (Analyst).
Revenue & profit by quarterScoutThree years of results from SEC filings, growth marked quarter by quarter.
Insider buying vs selling by quarterScoutStreaks like “7 quarters of net selling” spotted for you.
Who owns it (13F)ScoutTop funds, who added, who cut and who sold out last quarter.
Congress tradesFreeEvery House and Senate trade in the stock, late filers flagged.
Dilution trackerAnalystStock offerings, shelf registrations and share-count growth, scored.
Snapshot for your trading styleAnalystDay trading, swing trading and long-term numbers side by side.
Free plan: insider trades, insider signal and Congress trades. Sections marked
Scout or Analyst unlock with that plan (from $29/month). Screenshots: Micron Technology report, Oct 19, 2026.
Are insiders buying or selling AVBP stock?
In the last 12 months ArriVent BioPharma, Inc. insiders made open-market purchases worth about $0 and sales worth about $13 million. Data comes from SEC Form 4 filings, updated every 30 minutes on CapitalSnitch.
When was the last insider trade in AVBP?
The most recent open-market insider trade in AVBP was filed on 2026-02-03.
How many institutions own AVBP?
158 investment managers reported holding AVBP in SEC Form 13F filings for Q2 2026.
Has any member of Congress traded AVBP?
No congressional trades in AVBP were reported in the past two years. The full list is free on CapitalSnitch.
Free weekly email: the week's biggest insider buys and Congress trades, every Monday. No spam, one-click unsubscribe.
Public-record data for research and education, not investment advice. Insider sales are often pre-planned (10b5-1).
Congress data: Data derived from public disclosures filed under the Ethics in Government Act and the STOCK Act, republished free for public transparency and news reporting. Disclosures may lag the trade by 45 days or more and show amounts only as ranges. This data may not be used for credit rating, loan underwriting, solicitation of money (political, charitable or other), direct-mail or commercial targeting (5 U.S.C. 13107).
